Willem M. Smit

1.5k total citations
36 papers, 934 citations indexed

About

Willem M. Smit is a scholar working on Oncology, Hematology and Reproductive Medicine. According to data from OpenAlex, Willem M. Smit has authored 36 papers receiving a total of 934 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 13 papers in Hematology and 7 papers in Reproductive Medicine. Recurrent topics in Willem M. Smit's work include Cancer Treatment and Pharmacology (10 papers), Chronic Myeloid Leukemia Treatments (10 papers) and Ovarian cancer diagnosis and treatment (7 papers). Willem M. Smit is often cited by papers focused on Cancer Treatment and Pharmacology (10 papers), Chronic Myeloid Leukemia Treatments (10 papers) and Ovarian cancer diagnosis and treatment (7 papers). Willem M. Smit collaborates with scholars based in Netherlands, United States and Belgium. Willem M. Smit's co-authors include J.H. Frederik Falkenburg, Roel Willemze, Cornelis A.M. van Bergen, Willem E. Fibbe, Ellie G.A. Lurvink, Hanneke C. Kluin‐Nelemans, J. E. Landegent, Petra Kluck, Amon R. Wafelman and Peter Joosten and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.

In The Last Decade

Willem M. Smit

36 papers receiving 908 citations

Peers

Countries citing papers authored by Willem M. Smit

Since Specialization

Citations

This map shows the geographic impact of Willem M. Smit's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Willem M. Smit with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Willem M. Smit more than expected).

Fields of papers citing papers by Willem M. Smit

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Willem M. Smit. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Willem M. Smit. The network helps show where Willem M. Smit may publish in the future.

Co-authorship network of co-authors of Willem M. Smit

This figure shows the co-authorship network connecting the top 25 collaborators of Willem M. Smit. A scholar is included among the top collaborators of Willem M. Smit based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Willem M. Smit. Willem M. Smit is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Switching from imatinib to nilotinib plus pegylated interferon-α2b in chronic phase CML failing to achieve deep molecular response: clinical and immunological effects 2023 ·Annals of Hematology ·(unknown), (unknown), Mette Ilander, (unknown), Satu Mustjoki, Johan Richter, Nicole M. A. Blijlevens, Willem M. Smit, Bjørn Tore Gjertsen, Tobias Gedde‐Dahl, Berit Markevärn, (unknown), Peter E. Westerweel, Henrik Hjorth‐Hansen, Jeroen J. W. M. Janssen	5
2	Response and Adherence to Nilotinib in Daily practice (RAND study): an in-depth observational study of chronic myeloid leukemia patients treated with nilotinib 2020 ·European Journal of Clinical Pharmacology ·Christel C. L. M. Boons, Lonneke Timmers, Jeroen J. W. M. Janssen, Peter E. Westerweel, Nicole M. A. Blijlevens, Willem M. Smit, Imke H. Bartelink, Janneke Wilschut, Eleonora L. Swart, N. Harry Hendrikse, Jacqueline G. Hugtenburg	7
3	Phase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancer 2015 ·Investigational New Drugs ·Ruud van der Noll, Willem M. Smit, A.N.M. Wymenga, David S. Boss, Mayer B. Grob, Alwin D. R. Huitema, Hilde Rosing, Matthijs M. Tibben, (unknown), (unknown), Jos H. Beijnen, Jan H.M. Schellens	8
4	Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: A randomised trial of the Dutch–Belgian Cooperative Trial for Haemato-Oncology (HOVON) 2013 ·European Journal of Cancer ·Noortje Thielen, Bronno van der Holt, Jan J. Cornelissen, Gregor Verhoef, (unknown), Bart J. Biemond, Simon Daenen, Wendy Deenik, (unknown), Eefke Petersen, Willem M. Smit, Peter J.M. Valk, Gert J. Ossenkoppele, Jeroen J. W. M. Janssen	54
5	High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group 2013 ·Annals of Hematology ·Noortje Thielen, Bronno van der Holt, Gregor Verhoef, (unknown), Pieter Sonneveld, Jeroen J. W. M. Janssen, Wendy Deenik, J.H. Frederik Falkenburg, Marie José Kersten, Harm Sinnige, Martin R. Schipperus, A Schattenberg, (unknown), Willem M. Smit, (unknown), Peter J.M. Valk, Gert J. Ossenkoppele, Jan J. Cornelissen	6
6	A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study 2012 ·Annals of Oncology ·A.K.L. Reyners, Linda de Munck, Frans Erdkamp, Willem M. Smit, K. Hoekman, Roy Lalisang, H. de Graaf, A.N.M. Wymenga, M. Polée, Harry Hollema, Marcel A.T.M. van Vugt, Michael Schaapveld, P.H.B. Willemse	34
7	Randomized Phase II Study Comparing Efficacy and Safety of Combination-Therapy Trastuzumab and Docetaxel vs. Sequential Therapy of Trastuzumab Followed by Docetaxel Alone at Progression As First-Line Chemotherapy in Patients with HER2+ Metastatic Breast Cancer: HERTAX Trial 2011 ·Clinical Breast Cancer ·Paul Hamberg, Monique M.E.M. Bos, Hans J. Braun, Jacqueline M. Stouthard, (unknown), Frans Erdkamp, (unknown), M. Bontenbal, Geert-Jan Creemers, Johanneke E.A. Portielje, Hans Pruijt, O. J. L. Loosveld, Willem M. Smit, E.W. Muller, Paul Schmitz, Caroline Seynaeve, Jan G.M. Klijn	48
8	Determinants of Engagement in Face-to-Face and Online Patient Support Groups 2011 ·Journal of Medical Internet Research ·Cornelia F. van Uden–Kraan, Constance H.C. Drossaert, Erik Taal, Willem M. Smit, Hein J. Bernelot Moens, Mart AFJ van de Laar	46
9	Weekly docetaxel in metastatic breast cancer patients: No superior benefits compared to three-weekly docetaxel 2011 ·European Journal of Cancer ·Carolien P. Schröder, Linda de Munck, Anneke M. Westermann, Willem M. Smit, Geert-Jan Creemers, Hiltje de Graaf, Jacqueline M. Stouthard, (unknown), Z. Erjavec, Aart van Bochove, Willemijn Vader, Pax H.B. Willemse	26
10	A phase III study on the efficacy and safety of docetaxel, every three weeks or as a weekly regimen in patients with metastatic breast cancer 2007 ·Breast Cancer Research and Treatment ·(unknown), Linda de Munck, G.J. Creemers, H. de Graaf, Willem M. Smit, Z. Erjavec, Jacqueline M. Stouthard, (unknown), Aart van Bochove, Willemijn Vader, (unknown)	1
11	High-vs low-dose cytarabine combined with interferon alfa in patients with first chronic phase chronic myeloid leukemia. A prospective randomized phase III study 2006 ·Annals of Hematology ·Wendy Deenik, Bronno van der Holt, G. Verhoef, A Schattenberg, LF Verdonck, Simon Daenen, Pierre Zachée, Petra H.M. Westveer, Willem M. Smit, Shulamiet Wittebol, Harry C. Schouten, Bob Löwenberg, G. J. Ossenkoppele, Jan J. Cornelissen	5
12	Classification and occurrence of clinically significant drug interactions with irinotecan and oxaliplatin in patients with metastatic colorectal cancer 2005 ·Clinical Therapeutics ·Frank G. A. Jansman, (unknown), Willem M. Smit, Jacques C. de Graaf, Jules L.L.M. Coenen, Dirk Th. Sleijfer, J. R. B. J. Brouwers	5
13	Clinical efficacy of three common treatments in acute otitis externa in primary care: randomised controlled trial 2003 ·BMJ ·F.A.M. van Balen, Willem M. Smit, Nicolaas P. A. Zuithoff, Theo Verheij	49
14	Results of ZD0473 in platinum-pretreated ovarian cancer: analysis according to platinum free interval 2002 ·European Journal of Cancer ·Martin Gore, R. Atkinson, H. Thomas, H. Curé, Danny Rischin, Philip Beale, Philippe Bougnoux, Luc Dirix, Willem M. Smit	8
15	A phase II trial of ZD0473 in platinum-pretreated ovarian cancer 2002 ·European Journal of Cancer ·Martin Gore, R. Atkinson, H. Thomas, H. Curé, Danny Rischin, Philip Beale, Philippe Bougnoux, Luc Dirix, Willem M. Smit	24
16	Cytotoxic T‐lymphocyte (CTL) responses against acute or chronic myeloid leukemia 1997 ·Immunological Reviews ·J.H. Frederik Falkenburg, Willem M. Smit, Roel Willemze	58
17	Generation of dendritic cells expressing bcr-abl from CD34-positive chronic myeloid leukemia precursor cells 1997 ·Human Immunology ·Willem M. Smit, (unknown), Cornelis A.M. van Bergen, Roelof A. de Paus, (unknown), (unknown), (unknown), JH Falkenburg	77
18	Interleukin-10, interleukin-12, and tumor necrosis factor-α differentially influence the proliferation of human CD8 + and CD4 + T-cell clones 1996 ·Annals of Hematology ·Cornelis A.M. van Bergen, Willem M. Smit, (unknown), (unknown), R. Willemze, J.H. Frederik Falkenburg	11
19	Generation of Donor-Derived Antileukemic Cytotoxic T-Lymphocyte Responses for Treatment of Relapsed Leukemia After Allogeneic HLA-Identical Bone Marrow Transplantation 1993 ·Journal of Immunotherapy ·JH Falkenburg, Simone A.P. van Luxemburg-Heijs, (unknown), (unknown), Willem M. Smit, P.J. Voogt, R. Willemze	40
20	Fulminant falciparum malaria 1990 ·Intensive Care Medicine ·Willem M. Smit, Heleen M. Oudemans–van Straaten, D. F. Zandstra	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact